Biodesix (BDSX) Stock Forecast & Price Target

Biodesix is attractive because its core Nodify franchise is benefiting from expanding clinical evidence, broader payor coverage, and a sales model that is steadily increasing test volume, with 2Q26 revenue up 34.2% YoY to $26.9M and diagnostic testing revenue up 41.6% to $25.4M. Its gross margin of 82%, narrowed adjusted EBITDA loss of $3.2M, and management’s expectation of positive adjusted EBITDA on a run-rate basis suggest improving operating leverage as operating expenses rose only 7% while revenue surged. Long-term upside is further supported by the two-pronged MRD strategy, first-mover positioning in a market with limited direct competition, and capacity to support growth for the next 2-3 years without significant capex.

Biodesix is facing a fragile financial profile, with only $30.0M in cash against $50.0M of debt at the end of June 2026 and negative operating cash flow of ($1.6M) in 2Q26, which increases the likelihood of additional capital raises within the next 12 months. Its revenue base is exposed to reimbursement uncertainty, since Medicare represented 21% of total revenue in 2023 and 23% in 2022, while commercial payor coverage for three of four lung cancer tests still depends on securing in-network contracts. As a small public company with meaningful spending needs for sales and marketing, R&D, regulatory clearance, and laboratory expansion, Biodesix may struggle to fund growth and reach profitability without further strain on shareholders and earnings.